Canaccord Genuity Group Inc. CF-T -0.59% has lured a team of advisers with $1-billion of client assets from Canadian Imperial ...

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today ...

Canaccord Genuity Group (TSE:CF – Free Report) had its price target raised by TD Securities from C$10.00 to C$12.00 in a ...

Canaccord Genuity Group (TSE:CF – Free Report) had its target price lifted by Cormark from C$11.50 to C$12.50 in a report issued on Tuesday,BayStreet.CA reports. Cormark also issued estimates for ...

Fintel reports that on November 13, 2024, Canaccord Genuity downgraded their outlook for Doximity (NYSE:DOCS) from Buy to ...

Fintel reports that on November 13, 2024, Canaccord Genuity upgraded their outlook for Viant Technology (NasdaqGS:DSP) from ...

About Elutia Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of ...

On Wednesday, Blend Labs Inc (BLND) stock saw a decline, ending the day at $4.36 which represents a decrease of $-0.19 or -4.18% from the prior close of $4.55. The stock opened at $4.59 and touched a ...

In a report released today, Charlie Sharp from Canaccord Genuity reiterated a Buy rating on Vaalco Energy (EGY – Research Report), with a price target of p685.00. The company’s shares opened today at ...

Doximity (DOCS) stock falls as Canaccord Genuity downgrades it to hold from buy, on high expectations reflected in its shares after earnings-led rally. Read more here.

Canaccord Genuity Group Inc. recorded strong growth in wealth-management and capital-markets divisions for its fiscal second ...

Canaccord Genuity Group Inc (TSX:CF) is set to release its Q2 2025 earnings on Nov 7, 2024. The consensus estimate for Q2 2025 revenue is $0.43 million, and the earnings are expected to come in at $0.